[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-malignant-tumors\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-malignant-tumors":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100574466","phase-1-a-clinical-trial-to-assess-com503-in-participants-with-advanced-solid-malignancies-100574466",false,"NCT06759649","A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies","A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies","Inclusion Criteria:\n\n* Participants with histologically\u002Fcytologically confirmed advanced recurrent or metastatic solid tumor malignancy\n* Part 1 (dose escalation): Participants must have had disease progression on or following all available standard of care (SOC) therapies known to confer clinical benefit.\n* Part 2 (dose expansion): Participants may be enrolled following disease progression that has progressed after at least 1 available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized SOC.\n* Participants must have a solid tumor measurable by computed tomography (CT) or magnetic resonance imaging (MRI) as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) criteria by investigator assessment\n\nExclusion Criteria:\n\n* History of another malignancy within 2 years prior to the first trial intervention administration (unless the malignancy was treated with curative intent with low risk of recurrence \\[e.g., nonmelanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar\\] which are allowed to enroll).\n* Therapy with Immunosuppressive doses of systemic medications, such as steroids (doses \\>10 mg\u002Fday prednisone or equivalent daily) within 2 weeks before trial intervention administration\n* Have known active central nervous system (CNS) metastases and\u002For leptomeningeal disease (LMD).\n* Active and clinically relevant bacterial, fungal, or viral infection that is not controlled or requires systemic antibiotics, antifungals, or antivirals, respectively.\n* Ascites or pleural effusion that is symptomatic and\u002For requiring drainage within 2 weeks prior to the first trial intervention administration.\n* Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or participants with human immunodeficiency virus (HIV).\n* Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the participant's participation in the trial.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors.\n\nThe primary objectives of this study are:\n\n* To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors.\n* To identify the maximum tolerated dose (MTD) \u002F maximum administered dose (MAD) and\u002For the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.",[26,27],"Neoplasm","Cancer, Malignant Tumors",[29,30,31,32],"first-in-human","oncology","monoclonal antibody","immunotherapy","RECRUITING","2026-02-26",{"date":36,"type":37},"2026-02-27","ACTUAL",{"date":39,"type":37},"2025-01-07",{"date":41,"type":20},"2027-11-22",{"name":43,"class":44},"Compugen Ltd","INDUSTRY",11,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":67,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100591303","neurolytic-block-techniques-in-abdominal-visceral-cancer-pain-100591303","NCT06978673","Neurolytic Block Techniques In Abdominal Visceral Cancer Pain","Comparison of Neurolytic Block Techniques for the Treatment of Abdominal Visceral Pain and Their Influence On The Quality of Life of Patients With Cancer","CONCERN","Inclusion Criteria:\n\nPatients aged 18 years or older Presence of localized visceral pain in the upper abdomen originating from cancer of the stomach, duodenum, distal esophagus, ascending or transverse colon, liver, biliary tract, or pancreas\n\nIneffectiveness of analgesic treatment with third-step opioids according to the WHO analgesic ladder, including:\n\nOpioids (≥ 60 mg\u002Fday of morphine equivalents) Antidepressants (tricyclic or dual-action), at any dosage Gabapentinoids, at any dosage Presence of side effects from analgesics that are difficult to manage with medication\n\nExclusion Criteria:\n\nPresence of ascites Presence of deep vein thrombosis Presence of hepatic failure: Child-Pugh class B or C Presence of renal failure: estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² Use of any anticoagulant medication\n\nClinical coagulation disorder, defined as:\n\nINR \\> 1.5 Prothrombin activity \\\u003C 70% or prothrombin time \\> 13.5 seconds aPTT \\> 40 seconds Cardiovascular failure: NYHA class III",{"count":55,"type":20},64,[57],"NA","The neurolytic blocks of sympathetic chains are commonly used for the treatment of cancer-related pain. This study aims to compare celiac plexus neurolysis and splanchnic nerve neurolysis for the treatment of abdominal visceral pain and its influence on the quality of life of patients with cancer.",[27,60,61,62,63,64,65,66],"Abdominal Cancer","Cancer Pain","Visceral Pain","Cancer-related Pain","Pain Management","Celiac Ganglia","Sympathetic Ganglia",[68,69,70,71,72,73,74,75,76,77,78],"cancer pain","visceral pain","abdominal cancer","cancer","abdominal pain","cancer-related pain","pain management","neurolytic block","splanchnic nerve block","celiac plexus block","sympathetic neurolysis","NOT_YET_RECRUITING","2025-05-30",{"date":82,"type":37},"2025-06-03",{"date":80,"type":20},{"date":85,"type":20},"2026-12",{"name":87,"class":88},"Instituto do Cancer do Estado de São Paulo","OTHER",1]